Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TORL-2-307-MAB
- Development stage
- Phase 1
- Lead developer
- TORL BioTherapeutics
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TORL-2-307-MAB is a humanized IgG1 monoclonal antibody that specifically targets and inhibits Claudin 18.2 (CLDN18.2), a tight junction protein overexpressed in certain cancers such as gastric and pancreatic cancer. By binding to CLDN18.2 on tumor cells, the antibody may induce cell death and inhibit tumor proliferation through immune-mediated mechanisms[1][3][4]. It is being developed by TORL Biotherapeutics for the treatment of various advanced solid tumors including gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, and other gastrointestinal malignancies[4][5]. The drug is currently in Phase 1 clinical trials in the United States and South Korea[4][5].
- Other names
- anti-Claudin18.2 monoclonal antibodyanti-Claudin-18.2 monoclonal antibodyanti-Claudin 18.2 monoclonal antibody
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on TORL-2-307-MAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TORL-2-307-MAB.